Lansoprazole Capsule, Delayed Release
Product Images NDC 67296-2270

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 67296-2270). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Lansoprazole Delayed-Release Capsules USP 15 mg by Dr. Reddy's Laboratories Limited. The label indicates the product is Rx only and contains 10 capsules (1 x 10 unit-dose). It includes storage instructions, a medication guide notice, and the NDC 55111-398-79. The label also notes the capsules are imprinted with RDY and LAN for identification.*

FDA Label Image

Carton2 (Carton2)

Lansoprazole Delayed-Release Capsules USP 30 mg carton containing 10 capsules (1 x 10 unit-dose) labeled for oral use. The label notes each delayed-release capsule contains 30 mg lansoprazole. It is a prescription drug by Redpharm Drug and manufactured by Dr. Reddy's Laboratories Limited. Packaging includes storage instructions, prescription warnings, and a medication guide notice.*

FDA Label Image

Container1 (Container1)

Label for Lansoprazole Delayed-Release Capsules USP, 15 mg, oral dosage form. The label indicates a package size of 90 capsules, prescription only. Labeler is Dr. Reddy's. The label includes a medication guide reference URL and barcode.*

FDA Label Image

Container2 (Container2)

Label for Lansoprazole delayed-release capsules, USP 30 mg, by Redpharm Drug. The label states the product contains 90 capsules for oral use, includes storage instructions, a QR code linking to the medication guide, and cautions it is for prescription use only. The label also features the brand Dr. Reddy's and a barcode with relevant product codes.*

FDA Label Image

Figure1 (Figure1)

A line graph showing mean severity of day heartburn over time for evaluable patients, with severity rated from 0 (none) to 3 (severe). The graph compares placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily across approximately 60 days from treatment start, indicating decreasing heartburn severity over time with lansoprazole doses compared to placebo.*

FDA Label Image

Figure2 (Figure2)

This line graph depicts the mean severity of night heartburn over time, measured from the start of treatment for evaluable patients. The chart compares severity levels (0=none to 3=severe) for three groups: placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, across approximately 60 days.*

FDA Label Image

Structure (Structure)

Chemical structure of lansoprazole shown as a molecular diagram with labeled atoms and bonds illustrating its benzimidazole and substituted pyridine components, including a sulfoxide linker and trifluoromethoxy group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.